Evidence map›Paper›PMID 37859403›Full record

ArticleInternational journal of immunopathology and pharmacology

The impact of hepatitis B virus and hepatitis C virus infections in patients with Hodgkin's and non-Hodgkin's lymphoma.

Dalia Y Kadry, Mostafa A Elbahnasawy, Mohamed Tm Mansour, Omnia K El Gebaly, Hala Aziz, Mahmoud M Kamel, Ahmed S Abdel-Moneim, Samah Radwan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Molecular characterization and antibiotic susceptibility of methicillin-resistantInternational journal of immunopathology and pharmacology
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Dalia Y KadryClinical Pathology Department and Microbiology Lab, National Cancer Institute, Cairo University, Cairo, Egypt.ORCID 0000-0001-7697-941X
Mostafa A ElbahnasawyBotany and Microbiology Department, Faculty of Science, Al-Azhar University, Cairo, Egypt.ORCID 0000-0002-1749-3388
Mohamed Tm MansourMedical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Omnia K El GebalyClinical Pathology Department and Microbiology Lab, National Cancer Institute, Cairo University, Cairo, Egypt.
Hala AzizMedical Oncology Department, National Cancer Institute, Cairo University, Cairo, Egypt.ORCID 0000-0003-4864-2224
Mahmoud M KamelClinical Pathology Department and Microbiology Lab, National Cancer Institute, Cairo University, Cairo, Egypt.
Ahmed S Abdel-MoneimMicrobiology Department, College of Medicine, Taif University, Al-Taif, Saudi Arabia.ORCID 0000-0002-3148-6782
Samah RadwanClinical Pathology Department and Microbiology Lab, National Cancer Institute, Cairo University, Cairo, Egypt.
Cairo University · EGAl-Azhar University · EGTaif University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to determine the prevalence of HCV and occult HBV among newly diagnosed pre-treatment Egyptian lymphoma patients and evaluate patients' outcomes based on the presence of the viral infections.

methodsThe study included 80 therapy-naïve lymphoma patients including 71 non-Hodgkin lymphoma (NHL) and 9 Hodgkin lymphoma disease (HD) in addition to 100 healthy volunteers. HBV screening using HBsAg and anti-HBc IgM and HCV using AB/Ag ELISA and real-time RT-PCR were screened in tested and control groups. The diagnosis was confirmed by histopathology. Overall survival (OS) and progression-free survival (PFS) were conducted to diseased patients.

resultsHealthy patients showed 4/100, (4%) active HCV infection and 1/100, (1%) active HBV infection and no occult HBV infection. Among NHL patients, 28 were positive for HBV (6 active and 22 occult HBV infection). Occult HBV was also detected in 5/9 HD patients. HCV was detected in (30/71, 42.3%) of NHL patients and in a single HD patient. Ten occult HBV NHL patients showed a mixed infection with HCV. The incidence of both HCV and HBV are higher in NHL than HL patients. After antitumor treatment, complete remission for lymphoma was achieved in 45% of patients. Both overall survival (OS) and progression-free survival (PFS) were correlated and significantly associated with patients' LDH levels.

conclusionsOur findings claim the suggestive role of HCV and occult HBV infections in NHL but not HL patients in comparison to healthy control, suggesting pre-screening of related factors including occult HBV in for potential better therapy response.

Indexed as

Hepatitis BHepatitis CLymphoma, Non-HodgkinHepacivirusHepatitis B virusHumansco-infectionlymphomaoccult HBVoverall survivalprogression-free survival

Identifiers

PMID37859403
PMCPMC10588407
OpenAlexW4387798520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.